Eleclazine hydrochloride is primarily used in the field of cardiology as an investigational antiarrhythmic agent. It targets the late sodium current in cardiac cells, which plays a significant role in the development of arrhythmias, particularly in conditions like long QT syndrome. By inhibiting this current, it helps stabilize the heart's electrical activity, reducing the risk of abnormal heart rhythms. Its application is particularly relevant in treating ventricular arrhythmias, where conventional therapies may be insufficient or pose significant side effects. Research continues to explore its potential in improving outcomes for patients with various forms of cardiac electrical disturbances.